Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jun;77(12):2199–2203. doi: 10.1038/bjc.1998.366

BRCA1 mutations in southern England.

D M Eccles 1, P Englefield 1, M A Soulby 1, I G Campbell 1
PMCID: PMC2150412  PMID: 9649133

Abstract

If genetic testing for breast and ovarian cancer predisposition is to become available within a public health care system there needs to be a rational and cost-effective approach to mutation analysis. We have screened for BRCA1 mutations in 230 women with breast cancer, all from the Wessex region of southern England, in order to establish the parameters on which to base a cost-effective regional mutation analysis strategy. Truncating mutations were detected in 10/155 (6.5%) consecutive cases selected only for diagnosis under the age of 40 (nine of these ten women had a strong family history of breast or ovarian cancer), 3/61 (4.9%) bilateral-breast cancer cases (all three mutations occurring among women for whom the first cancer was diagnosed under 40 years) and 8/30 (26.6%) breast cancer cases presenting to the genetics clinic (for whom a strong family history of breast and/or ovarian cancer was present). Ten different mutations were detected in 17 families, but three of these accounted for 10/17 (59%) of the families. The cost of screening the population for mutations in the entire BRCA1 gene is unacceptably high. However, the cost of screening a carefully selected patient cohort is low, the risk of misinterpretation much less and the potential clinical benefits clearer.

Full text

PDF
2199

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker D. F., Almeida E. R., Casey G., Fain P. R., Liao S. Y., Masunaka I., Noble B., Kurosaki T., Anton-Culver H. BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. Genet Epidemiol. 1996;13(6):595–604. doi: 10.1002/(SICI)1098-2272(1996)13:6<595::AID-GEPI5>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  2. Claus E. B., Risch N., Thompson W. D. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991 Feb;48(2):232–242. [PMC free article] [PubMed] [Google Scholar]
  3. Easton D. Breast cancer genes--what are the real risks? Nat Genet. 1997 Jul;16(3):210–211. doi: 10.1038/ng0797-210. [DOI] [PubMed] [Google Scholar]
  4. Eccles D., Marlow A., Royle G., Collins A., Morton N. E. Genetic epidemiology of early onset breast cancer. J Med Genet. 1994 Dec;31(12):944–949. doi: 10.1136/jmg.31.12.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eeles R. Testing for the breast cancer predisposition gene, BRCA1. BMJ. 1996 Sep 7;313(7057):572–573. doi: 10.1136/bmj.313.7057.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ford D., Easton D. F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995 Dec;57(6):1457–1462. [PMC free article] [PubMed] [Google Scholar]
  7. Gayther S. A., Warren W., Mazoyer S., Russell P. A., Harrington P. A., Chiano M., Seal S., Hamoudi R., van Rensburg E. J., Dunning A. M. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995 Dec;11(4):428–433. doi: 10.1038/ng1295-428. [DOI] [PubMed] [Google Scholar]
  8. Healy B. BRCA genes--bookmaking, fortunetelling, and medical care. N Engl J Med. 1997 May 15;336(20):1448–1449. doi: 10.1056/NEJM199705153362009. [DOI] [PubMed] [Google Scholar]
  9. Iselius L., Littler M., Morton N. Transmission of breast cancer--a controversy resolved. Clin Genet. 1992 Apr;41(4):211–217. doi: 10.1111/j.1399-0004.1992.tb03665.x. [DOI] [PubMed] [Google Scholar]
  10. Langston A. A., Malone K. E., Thompson J. D., Daling J. R., Ostrander E. A. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996 Jan 18;334(3):137–142. doi: 10.1056/NEJM199601183340301. [DOI] [PubMed] [Google Scholar]
  11. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  12. Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1041–1049. [PMC free article] [PubMed] [Google Scholar]
  13. Rebbeck T. R., Couch F. J., Kant J., Calzone K., DeShano M., Peng Y., Chen K., Garber J. E., Weber B. L. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet. 1996 Sep;59(3):547–553. [PMC free article] [PubMed] [Google Scholar]
  14. Richards C. S., Ward P. A., Roa B. B., Friedman L. C., Boyd A. A., Kuenzli G., Dunn J. K., Plon S. E. Screening for 185delAG in the Ashkenazim. Am J Hum Genet. 1997 May;60(5):1085–1098. [PMC free article] [PubMed] [Google Scholar]
  15. Schubert E. L., Lee M. K., Mefford H. C., Argonza R. H., Morrow J. E., Hull J., Dann J. L., King M. C. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet. 1997 May;60(5):1031–1040. [PMC free article] [PubMed] [Google Scholar]
  16. Serova O. M., Mazoyer S., Puget N., Dubois V., Tonin P., Shugart Y. Y., Goldgar D., Narod S. A., Lynch H. T., Lenoir G. M. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet. 1997 Mar;60(3):486–495. [PMC free article] [PubMed] [Google Scholar]
  17. Stoppa-Lyonnet D., Laurent-Puig P., Essioux L., Pagès S., Ithier G., Ligot L., Fourquet A., Salmon R. J., Clough K. B., Pouillart P. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet. 1997 May;60(5):1021–1030. [PMC free article] [PubMed] [Google Scholar]
  18. Struewing J. P., Abeliovich D., Peretz T., Avishai N., Kaback M. M., Collins F. S., Brody L. C. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995 Oct;11(2):198–200. doi: 10.1038/ng1095-198. [DOI] [PubMed] [Google Scholar]
  19. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  20. Struewing J. P., Tarone R. E., Brody L. C., Li F. P., Boice J. D., Jr BRCA1 mutations in young women with breast cancer. Lancet. 1996 May 25;347(9013):1493–1493. doi: 10.1016/s0140-6736(96)91732-8. [DOI] [PubMed] [Google Scholar]
  21. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J. G., Tryggvadottir L., Tulinius H., Eyfjörd J. E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997 May;60(5):1079–1084. [PMC free article] [PubMed] [Google Scholar]
  22. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES